Superoxide Dismutase 2 Protein Levels in Blood May Act as a Prognostic Marker for High-Risk Neuroblastoma Patients
| dc.contributor.author | Demir, Ayse Banu | |
| dc.contributor.author | Altun, Zekiye | |
| dc.contributor.author | Aktas, Safiye | |
| dc.contributor.author | Olgun, Nur | |
| dc.date.accessioned | 2023-06-16T14:40:42Z | |
| dc.date.available | 2023-06-16T14:40:42Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | Purpose: Determination of proteomic differences plays an important role in biomarker investigations. Due to its heterogenic molecular background, identification of certain biomarkers is still a demand both for diagnosis and prognosis of neuroblastoma. In this study, it is aimed to identify marker proteins/mechanisms that may play role in neuroblastoma prognosis. Material and Methods: Real-time PCR analyses were performed for 2p24.3, 11q23, 1p36 and 17q25 status from tumor samples of the patients to determine the risk groups. A proteomic approach was used for different risk groups of the disease by using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF/TOF) approach. Mononuclear cell pools from blood samples of patients for different risk groups were constructed and protein expression changes for different groups were identified. Results: Manganese-superoxide dismutase (SOD2) protein was found to significantly increase in high -risk group of neuroblastoma patients. Conclusion: Our results showed that SOD2 may play an important role in neuroblastoma progression and be a candidate prognostic peripheral blood marker for neuroblastoma patients. | en_US |
| dc.description.sponsorship | Turkish Pediatric Oncology Group (TPOG) | en_US |
| dc.description.sponsorship | This study has been supported by a research grant of Turkish Pediatric Oncology Group (TPOG) (2015) and performed on behalf of TPOG | en_US |
| dc.identifier.doi | 10.30621/jbachs.1071115 | |
| dc.identifier.issn | 2458-8938 | |
| dc.identifier.issn | 2564-7288 | |
| dc.identifier.uri | https://doi.org/10.30621/jbachs.1071115 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14365/2450 | |
| dc.language.iso | en | en_US |
| dc.publisher | Dokuz Eylul Univ Inst Health Sciences | en_US |
| dc.relation.ispartof | Journal of Basıc And Clınıcal Health Scıences | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Neuroblastoma | en_US |
| dc.subject | SOD2 | en_US |
| dc.subject | risk-classification | en_US |
| dc.subject | proteomics | en_US |
| dc.subject | MALDI-TOF | en_US |
| dc.subject | TOF | en_US |
| dc.subject | International Criteria | en_US |
| dc.subject | Histone Modifications | en_US |
| dc.subject | Cancer-Cells | en_US |
| dc.subject | Expression | en_US |
| dc.subject | Identification | en_US |
| dc.subject | Proteomics | en_US |
| dc.subject | Diagnosis | en_US |
| dc.subject | Biology | en_US |
| dc.subject | Stress | en_US |
| dc.subject | Define | en_US |
| dc.title | Superoxide Dismutase 2 Protein Levels in Blood May Act as a Prognostic Marker for High-Risk Neuroblastoma Patients | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C5 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Ekonomi Üniversitesi | en_US |
| gdc.description.departmenttemp | [Demir, Ayse Banu] Izmir Univ Econ, Fac Med, Dept Med Biol, Izmir, Turkey; [Altun, Zekiye; Aktas, Safiye] Univ Dokuz Eylul, Inst Oncol, Dept Basic Oncol, Izmir, Turkey; [Olgun, Nur] Univ Dokuz Eylul, Inst Oncol, Dept Pediat Oncol, Izmir, Turkey | en_US |
| gdc.description.endpage | 213 | en_US |
| gdc.description.issue | 1 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | N/A | |
| gdc.description.startpage | 196 | en_US |
| gdc.description.volume | 7 | en_US |
| gdc.description.wosquality | Q4 | |
| gdc.identifier.openalex | W4313473830 | |
| gdc.identifier.wos | WOS:000933151700021 | |
| gdc.index.type | WoS | |
| gdc.oaire.accesstype | GOLD | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 1.0 | |
| gdc.oaire.influence | 2.5252316E-9 | |
| gdc.oaire.isgreen | false | |
| gdc.oaire.keywords | Neuroblastoma;SOD2;Risk-classification;Proteomics;MALDI-TOF/TOF | |
| gdc.oaire.keywords | Health Care Administration | |
| gdc.oaire.keywords | Sağlık Kurumları Yönetimi | |
| gdc.oaire.popularity | 2.8063318E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 0301 basic medicine | |
| gdc.oaire.sciencefields | 0303 health sciences | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.openalex.collaboration | National | |
| gdc.openalex.fwci | 0.2105 | |
| gdc.openalex.normalizedpercentile | 0.52 | |
| gdc.opencitations.count | 1 | |
| gdc.plumx.mendeley | 2 | |
| gdc.virtual.author | Demir, Ayşe Banu | |
| gdc.wos.citedcount | 1 | |
| relation.isAuthorOfPublication | ecd1c9da-04b3-4522-813f-ee86b06b7d1b | |
| relation.isAuthorOfPublication.latestForDiscovery | ecd1c9da-04b3-4522-813f-ee86b06b7d1b | |
| relation.isOrgUnitOfPublication | 4cbb0a74-ee1a-438b-b714-b8ef253df94b | |
| relation.isOrgUnitOfPublication | fbc53f3e-d1d3-4168-afd8-e42cd20bddd9 | |
| relation.isOrgUnitOfPublication | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 4cbb0a74-ee1a-438b-b714-b8ef253df94b |
Files
Original bundle
1 - 1 of 1
